Navigation Links
Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
Date:8/30/2011

REDWOOD CITY, Calif., Aug. 30, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil® Aerolizer® in patients with moderate-to-severe COPD. All doses of FF MDI tested produced highly statistically significant improvements in lung function (FEV1 AUC 0-12) compared to placebo (p<0.0001). Dose ordering (incremental increase in efficacy with increasing doses) was observed across the three FF MDI doses evaluated, and the two lower doses tested were comparable to 12 mcg Foradil, the currently approved dose. This study marks the fourth in a series of detailed clinical evaluations of FF by Pearl in its novel MDI formulation platform, and significantly expands the safety and efficacy database of FF MDI. Detailed results of this study will be presented at a future conference.

"Successful completion of this study is an important milestone in the development of PT003, Pearl's combination of FF with glycopyrrolate, a long acting muscarinic antagonist (LAMA). The dose ordering and consistent response observed in this study confirm the robustness of Pearl's breakthrough formulation platform, and strengthen the value of FF MDI as the LABA arm of the PT003 program," commented Colin Reisner, Pearl's chief medical officer and executive vice president of clinical development. "The totality of data from this and previous studies provides Pearl with the confidence to select a dose of FF MDI to progress into PT003 Phase 3 studies."

Chuck Bramlage, Pearl's chief executive officer added, "This study was completed in only three months, demonstrating the drive of the Pearl development
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
3. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
4. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
5. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
6. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
7. Prime Therapeutics Drug Trend Insights Reports One of the Lowest Drug Spending Increases in the Industry
8. Precision Therapeutics Named on Inc. 500
9. 5000 2011 List and Recognized for Achievements in Personalized Medicine Industry
10. Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
11. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... Aug. 4, 2015 Among 1,000 U.S. consumers, ... only half of consumers surveyed are aware of prescription ... used use them, according to findings from a new ... service partnership focused on improving the health and well-being ... survey polled 1,000 men and women, ages 21 and ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... financial results for the three month period ended June 30, ... Non-GAAP 1 Highlights: , Revenue ... currency. , North American product sales grew 45% year-over-year. ... constant currency, including 14% product growth in the EMEA region ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 2PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 3PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 4PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 5PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 7
(Date:8/4/2015)... ... 04, 2015 , ... Sin City Gallery is delighted to ... diverse group of exceptionally talented female artists. The exhibition premieres at the ... 25-27, 2015 in Downtown Las Vegas. Curated by gallery director Dr. Laura Henkel, ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... ... METTLER TOLEDO has announced an upcoming online symposium entitled ... and Merck. This free online seminar will be held on September 24, ... decisions with limited process understanding. Established methods have been developed to facilitate ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
Breaking Medicine News(10 mins):Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... without gestational diabetes signals future heart risk, researcher says. , ... given to pregnant women may also show if they have ... new study has found. , This finding is important because ... for gestational diabetes to identify women who are at risk ...
... Aug. 24 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech, Inc. (OTC ... marketer of a variety of cactus-based products in,China, announced ... attend investor conference and meet with U.S. investors in ... roadshow details: , The company ...
... , WASHINGTON, Aug. 24 Secretary of ... (VA) is taking steps to assist Veterans seeking compensation for Post-Traumatic ... of war are being addressed vigorously and comprehensively by this administration ... century," said Secretary Shinseki. , , The VA ...
... , , AUBURN HILLS, ... (OTC Bulletin Board: ECOC), a leader in the discovery ... that it has signed a collaboration agreement with a ... for producing "fire standard compliant" (FSC) cigarettes. FSC cigarettes ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
... , , CINCINNATI and ARDEE, Ireland, Aug. 24, ... Warner Chilcott plc (Nasdaq: WCRX ) today announced an agreement for ... cash payment of $3.1 billion. , , To view ... m nr/pg/39814/ , , (Logo: ...
Cached Medicine News:Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 2Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 3Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 4Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 6Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 7Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 8
...
... Tupos LV/A+, the single-lead principle has been applied ... The complete system, which consists of the Tupos ... the scope of surgery and the risk of ... and the ventricle via a single lead. The ...
... ICD cardiac resynchronization and ICD device offers ... The unit's RV only sensing provides no ... LV depolarizations, eliminating this cause of inappropriate ... LV separation for optimized hemodynamics. Proven PR ...
... The Medtronic InSync II Marquis incorporates ... ICD therapy. Cardiac resynchronization benefits include ... pacing outputs to unique patient needs. ... functions that help physicians manage heart ...
Medicine Products: